Testosterone Cypionate Super-Responder Profile: Who Gets the Best Results?

Dose-Response Evidence

A 20-week study of 61 healthy men suppressed their own testosterone, then gave weekly testosterone enanthate at 25, 50, 125, 300 or 600 mg [1]. Mean nadir testosterone was 234, 289, 695, 1,344 and 2,435 ng/dL, and MRI thigh muscle volume changed by -4, +7, +15, +32 and +48 mL [1]. The study tested enanthate in healthy men, not cypionate in hypogonadal patients, and it did not identify which men respond best to cypionate [1].

Diagnosis and Dosing

The Depo-Testosterone label specifies 50 to 400 mg every 2 to 4 weeks by deep gluteal intramuscular injection [3]. It requires morning serum testosterone below normal on at least two separate days [3]. The Endocrine Society recommends symptoms plus consistently low testosterone, with extra testing when total testosterone is borderline or SHBG is altered [2]. TRAVERSE enrolled men with two fasting levels under 300 ng/dL [7].

Hematocrit

A meta-analysis of 29 trials in 3,393 men found mean hematocrit rose 4.0% with intramuscular enanthate or cypionate and 3.0% with gel; the difference between those two was not statistically significant [4]. A 3-year review of 178 men found hematocrit above 50% in 66.7% of injectable users, 12.8% on gels and 35.1% on pellets; the injectable group was younger and had higher baseline hematocrit, and the study was not randomized [5]. The Depo-Testosterone label says to check hemoglobin and hematocrit periodically [3].

Blood Pressure and Cardiovascular Data

FDA said in February 2025 that blood pressure studies confirmed an increase with all testosterone products [6]. The Depo-Testosterone label says to monitor blood pressure periodically and that testosterone products are not recommended in uncontrolled hypertension [3]. That label also still says some studies, but not all, have reported an increased risk of major adverse cardiovascular events, and it does not mention TRAVERSE [3]. TRAVERSE randomized 5,246 men aged 45 to 80 to testosterone gel or placebo; major adverse cardiovascular events occurred in 7.0% versus 7.3%, hazard ratio 0.96 (95% CI 0.78 to 1.17), over mean 33 months [7]. It tested gel, not injections, and no outcome trial of that size exists for injectable testosterone [7].

Other Label Flags

The Depo-Testosterone label says that with large doses of exogenous androgens, sperm production may be suppressed through FSH feedback [3]. It reports venous thromboembolism with testosterone products and says to discontinue treatment if it is suspected [3]. Depo-Testosterone contains testosterone, a Schedule III controlled substance [3]. The label says dosage is adjusted according to the patient's response and the appearance of adverse reactions [3].